ITM Isotope Technologies Munich

News

Akiram, ITM sign Lutetium-177 supply agreement

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

News

Manufacturing issues mar ITM's radiopharma filing, says FDA

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.

Oncology

pharmaphorum podcast Episode 264, ITM's Dr Andrew Cavey

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.

Oncology

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.

News

Telix prices $200m IPO in big week for radiopharma financing

Australian radiopharmaceutical specialist Telix has revealed the terms of its planned initial public offering (IPO) in the US, revealing that it hopes to raise $202 millio

Akiram, ITM sign Lutetium-177 supply agreement

Manufacturing issues mar ITM's radiopharma filing, says FDA

Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey

ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs

Telix prices $200m IPO in big week for radiopharma financing

ESC26: Can Arrowhead pierce Ionis' triglyceride armour?

Discover a new era of healthcare panel engagement: Grounded ...

ITM Isotope Technologies Munich

Editor's Picks